| 摘要 |
The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non- hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodie s and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD2 0 or anti-CD22 antibodies. The invention also provides combination therapies f or solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUSAN.RTM..
|
